Phase 3 Readout~month

Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in

Indication
Hypertriglyceridemia

Other upcoming events for ARWR

Phase 3 ReadoutPhase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in
Phase 3 ReadoutPhase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in
Phase 3 ReadoutPhase 3 Topline: Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in — ARWR Phase 3 Readout | BioSniper